

PRESS RELEASE - Ecully, April 7th, 2026

CELLforCURE launches a process to find a buyer for its Les Ulis site

CELLforCURE, a subsidiary of the SEQENS Group, has informed its employee representatives of its decision to look for a potential buyer for its site in Les Ulis (Essonne). CELLforCURE specializes in the development and the contract manufacturing of Cell & Gene therapies.

The primary objective of this initiative is to enable the continuation of an industrial activity on site, as part of a sustainable economic project, aligned with the specific requirements of innovative therapies. This decision is driven by a significant slowdown in Cell & Gene therapy funding, delays or cancellations of clinical projects, and a strong trend toward the relocation of bioproduction activities in the United States.

Since its acquisition by the SEQENS Group at the end of 2023, significant efforts have been undertaken to reposition CELLforCURE as a multi-client platform supporting a large range of customer projects. However, the site's activity has been severely impacted by the suspension or cancellation of numerous client projects, primarily for financial or industrial strategy reasons.

In this context and given the high level of fixed costs associated with the site's industrial and regulatory requirements, the SEQENS Group has decided to prioritize the search for a takeover solution. The objective is to ensure the continuation of CELLforCURE activities within a sustainable economic framework.

The aim is to reach a takeover solution in the upcoming months. Without a credible, industrial alternative, able to sustain CELLforCURE activities in the long run, and only in that case, the SEQENS Group may consider the complete cessation of the site activities.

CELLforCURE and the SEQENS Group are fully aware of the human challenges associated with this situation. CELLforCURE and SEQENS leadership teams consider employee support as a top priority and will engage, if necessary, in a thorough and responsible social dialogue to define the most appropriate measures to help impacted employees.

About CELLforCURE

CELLforCURE is a company specializing in the development and the contract manufacturing of cell and gene therapies, based in Les Ulis (Essonne). It is a subsidiary of the SEQENS Group.

Press contact: press@seqens.com